{"disease":{"id":"metastatic-pancreatic-adenocarcinoma","name":"metastatic pancreatic adenocarcinoma"},"drugs":{"marketed":[{"drug_id":"zenocutuzumab","indication_name":"advanced unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bizengri","generic_name":"ZENOCUTUZUMAB","company_name":"Merus N.V.","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Bizengri works by binding to a specific protein on cancer cells to block their growth and spread."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06445062","title":"Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":1130,"lead_sponsor_name":"Revolution Medicines, Inc.","has_results":false},{"nct_id":"NCT06989437","title":"A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":982,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05038254","title":"Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":750,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07409272","title":"A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":614,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT06608927","title":"Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":610,"lead_sponsor_name":"Arcus Biosciences, Inc.","has_results":false},{"nct_id":"NCT05254171","title":"Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Panbela Therapeutics, Inc.","has_results":false},{"nct_id":"NCT01365169","title":"Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients\"","phase":"NA","overall_status":"RECRUITING","enrollment_count":590,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07445295","title":"Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":558,"lead_sponsor_name":"Chipscreen Biosciences, Ltd.","has_results":false},{"nct_id":"NCT04935359","title":"Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":511,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04229004","title":"A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":502,"lead_sponsor_name":"Pancreatic Cancer Action Network","has_results":false},{"nct_id":"NCT06861088","title":"The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":480,"lead_sponsor_name":"Quercis Pharma AG","has_results":false},{"nct_id":"NCT03816163","title":"A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":393,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT07090499","title":"A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":310,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT05620134","title":"Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":263,"lead_sponsor_name":"Salubris Biotherapeutics Inc","has_results":false},{"nct_id":"NCT03126435","title":"EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":218,"lead_sponsor_name":"SynCore Biotechnology Co., Ltd.","has_results":true},{"nct_id":"NCT03611556","title":"MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":213,"lead_sponsor_name":"MedImmune LLC","has_results":true},{"nct_id":"NCT03943667","title":"Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":211,"lead_sponsor_name":"UNICANCER","has_results":true},{"nct_id":"NCT05383352","title":"A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":177,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT04233866","title":"Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":176,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT05933265","title":"Study of LP-184 in Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":175,"lead_sponsor_name":"Lantern Pharma Inc.","has_results":false},{"nct_id":"NCT04390763","title":"Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":164,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02376699","title":"Safety Study of SEA-CD40 in Cancer Patients","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":159,"lead_sponsor_name":"Seagen Inc.","has_results":false},{"nct_id":"NCT04469556","title":"Pancreatic Adenocarcinoma Signature Stratification for Treatment","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT06524973","title":"Telehealth Self-Management Coaching Sessions to Improve Quality of Life in Pancreatic Cancer Survivors and Their Family Care Givers","phase":"NA","overall_status":"RECRUITING","enrollment_count":136,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT05472259","title":"A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":134,"lead_sponsor_name":"Belgian Group of Digestive Oncology","has_results":false},{"nct_id":"NCT03214250","title":"Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":129,"lead_sponsor_name":"Parker Institute for Cancer Immunotherapy","has_results":true},{"nct_id":"NCT02890355","title":"FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":123,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02498613","title":"A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":122,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04821284","title":"Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Flemming Forsberg","has_results":false},{"nct_id":"NCT02600949","title":"Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":117,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06646055","title":"AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":110,"lead_sponsor_name":"Akeso","has_results":false},{"nct_id":"NCT05039177","title":"A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":101,"lead_sponsor_name":"Erasca, Inc.","has_results":false},{"nct_id":"NCT06018883","title":"Vitamin C to Chemotherapy Related Anemia in Pancreatic Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04888312","title":"Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":94,"lead_sponsor_name":"Alligator Bioscience AB","has_results":false},{"nct_id":"NCT05733000","title":"CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":94,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT05848154","title":"Application of ctDNA in Evaluation of Neoadjuvant Chemotherapy Efficacy and Exploration of Chemoresistance Mechanisms in Pancreatic Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":92,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT04005690","title":"Targeted Pathway Inhibition in Patients With Pancreatic Cancer","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT04548752","title":"Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":88,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01585805","title":"Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":88,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07410494","title":"Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":85,"lead_sponsor_name":"Essen Biotech","has_results":false},{"nct_id":"NCT06390059","title":"EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":84,"lead_sponsor_name":"NovoCure Ltd.","has_results":false},{"nct_id":"NCT05630183","title":"A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":81,"lead_sponsor_name":"Agenus Inc.","has_results":false},{"nct_id":"NCT01964287","title":"First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma.","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"Institut du Cancer de Montpellier - Val d'Aurelle","has_results":false},{"nct_id":"NCT01562899","title":"A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":77,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT02501902","title":"Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":76,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06147037","title":"A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06600906","title":"Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT06229496","title":"Dose Escalation and Dose Expansion Study of GAS in Subjects With Metastatic Pancreatic Adenocarcinoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT03331640","title":"A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":67,"lead_sponsor_name":"AIO-Studien-gGmbH","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}